0

Treatment of Latent Tuberculosis Infection-An Update

Moises A Huaman, Timothy R Sterling

Clin Chest Med. 2019 Dec;40(4):839-848.

PMID: 31731988

Abstract:

Treatment of latent tuberculosis infection (LTBI) is an important component of TB control and elimination. LTBI treatment regimens include once-weekly isoniazid plus rifapentine for 3 months, daily rifampin for 4 months, daily isoniazid plus rifampin for 3-4 months, and daily isoniazid for 6-9 months. Isoniazid monotherapy is efficacious in preventing TB disease, but the rifampin- and rifapentine-containing regimens are shorter and have similar efficacy, adequate safety, and higher treatment completion rates. Novel vaccine strategies, host immunity-directed therapies and ultrashort antimicrobial regimens for TB prevention, such as daily isoniazid plus rifapentine for 1 month, are under evaluation.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP54853-A Isoniazid Isoniazid 54-85-3 Price
qrcode